申请人:MERCK SHARP & DOHME
公开号:WO2016100051A1
公开(公告)日:2016-06-23
The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).
本发明提供了一种式(I)的化合物或其药用可接受的盐、酯和前药,它们是ERK2抑制剂。该发明还提供了一种抑制患有ERK2的患者的方法,包括向该患者施用至少一种式(I)的化合物的有效量。该发明还提供了一种治疗患有癌症的患者的方法,该方法包括向该患者施用至少一种式(I)的化合物的有效量。